TIDMEKF TIDMRENX

RNS Number : 5458G

EKF Diagnostics Holdings PLC

26 November 2020

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Sale of shares in Renalytix AI plc

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has sold 1,675,000 ordinary shares in Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) at a price of GBP4.60 per ordinary share, in response to strong institutional demand. The sale has resulted in gross proceeds of GBP7.705m to EKF and generated a profit of over GBP5.6m after dealing expenses.

Following this transaction EKF will continue to hold 1,002,981 ordinary shares in Renalytix AI plc.

 
     EKF Diagnostics Holdings plc                                        www.ekfdiagnostics.com 
     Christopher Mills, Non-executive Chairman                        Tel: +44 (0) 29 2071 0570 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer                                                              Tel: 020 7496 3000 
     Aubrey Powell / George Tzimas (Corporate 
      Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited                        Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com 
     Paul McManus / Lianne Cawthorne                   Mob: +44 (0) 7980 541 893 / +44 (0) 7584 
                                                                                        391 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFELLLBFLLFBD

(END) Dow Jones Newswires

November 26, 2020 02:00 ET (07:00 GMT)

Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Renalytix Charts.
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Renalytix Charts.